IMA

ImageneBio Inc

Add to Watchlist

Advanced Chart

8.290

-0.1(-1.192%)1D

Line

Candle

YTD

High

8.3861

Open

8.3861

VWAP

8.20

Vol

17.57K

Mkt Cap

92.70M

Low

8.080

Amount

144.15K

EV/EBITDA(TTM)

Total Shares

11.18M

-1.83M

EV/OCF(TTM)

P/S(TTM)

ImageneBio, Inc., formerly Ikena Oncology, Inc., is a clinical-stage biotechnology company. The Company is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The Company develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The Company is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.

1 Analyst Rating

Wall Street analysts forecast IMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMA is 30.00 USD with a low forecast of 30.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 8.290

Low

30.00

Averages

30.00

High

30.00

Current: 8.290

Low

30.00

Averages

30.00

High

30.00

Leerink

Outperform

initiated

$30

2025-10-24

Reason

Leerink

Price Target

$30

2025-10-24

initiated

Outperform

Reason

Leerink initiated coverage of ImageneBio (IMA) with an Outperform rating and $30 price target. The firm views shares as "dramatically undervalued," particularly following a selloff in the wake of disappointing competitor Sanofy's (SNY) amlitelimab results on September 4. Leerink believes ImageneBio's lead asset IMG-007, a non-depleting anti-OX40 monoclonal antibody, is a potential blockbuster for atopic dermatitis. Early clinical data for IMG-007 suggests compelling efficacy at Week 16 compared to Dupixent. Competing drug candidate Phase 3 disappointments from Amgen's (AMGN) OX40 rocatinlimab and Sanofi's OX40L amlitelimab have dampened investor sentiment toward the OX40-OX40L class. This yields a favorable setup for IMG-007 to deliver a superior "trifecta" competitive profile, the firm argues.

See All Ratings

Valuation Metrics

The current forward P/E ratio for ImageneBio Inc (IMA.O) is -2.35, compared to its 5-year average forward P/E of -3.06. For a more detailed relative valuation and DCF analysis to assess ImageneBio Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.06

Current PE

-2.35

Overvalued PE

-2.13

Undervalued PE

-3.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.19

Current PS

8.29

Overvalued PS

4.12

Undervalued PS

-1.73